MD20150122A2 - Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 - Google Patents

Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 Download PDF

Info

Publication number
MD20150122A2
MD20150122A2 MDA20150122A MD20150122A MD20150122A2 MD 20150122 A2 MD20150122 A2 MD 20150122A2 MD A20150122 A MDA20150122 A MD A20150122A MD 20150122 A MD20150122 A MD 20150122A MD 20150122 A2 MD20150122 A2 MD 20150122A2
Authority
MD
Moldova
Prior art keywords
dopamine
ligands
cognitive
heteroaromatic compounds
schizophrenia
Prior art date
Application number
MDA20150122A
Other languages
English (en)
Russian (ru)
Inventor
Майкл Аарон Бродни
Дженнифер Элизабет Даворен
Эми Бет ДУНАЙ
Иван Викторович Ефремов
Дэвид Лоренс Фирман ГРЭЙ
Майкл Эрик Грин
Жаклин Луиза ХЕНДЕРСОН
Чэвах ЛИ
Скот Ричард Мент
Стивен Виктор О`НЕЙЛ
Брюс Нелсэн РОДЖЕРС
Лэй Чжан
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51205521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20150122(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of MD20150122A2 publication Critical patent/MD20150122A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Conform prezentei invenţii se propun compuşi cu formula 1:şi sărurile farmaceutic acceptabile ale acestora; procedee de preparare a asemenea compuşi sau săruri; intermediari utilizaţi pentru prepararea acestora; compoziţii ce conţin asemenea compuşi sau săruri şi utilizarea lor pentru tratarea tulburărilor mediate de D1 (sau asociate cu D1) incluzând, de ex. schizofrenia (de ex., simptomele cognitive şi negative ale acesteia, tulburările cognitive (de ex., tulburările cognitive asociate cu schizofrenia, BA, BP sau farmacoterapia), declinul cognitiv legat de vârstă, demenţa şi boala Parkinson.
MDA20150122A 2013-06-27 2014-06-13 Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 MD20150122A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840144P 2013-06-27 2013-06-27
PCT/IB2014/062217 WO2014207601A1 (en) 2013-06-27 2014-06-13 Heteroaromatic compounds and their use as dopamine d1 ligands

Publications (1)

Publication Number Publication Date
MD20150122A2 true MD20150122A2 (ro) 2016-05-31

Family

ID=51205521

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150122A MD20150122A2 (ro) 2013-06-27 2014-06-13 Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1

Country Status (42)

Country Link
US (10) US9527831B2 (ro)
EP (2) EP3013813B1 (ro)
JP (1) JP6026024B2 (ro)
KR (1) KR101781723B1 (ro)
CN (1) CN105324376B (ro)
AP (1) AP2015008844A0 (ro)
AR (1) AR096748A1 (ro)
AU (1) AU2014300673B2 (ro)
BR (1) BR122023004130B1 (ro)
CA (1) CA2916653C (ro)
CL (1) CL2015003735A1 (ro)
CR (1) CR20150634A (ro)
CU (1) CU24334B1 (ro)
DK (2) DK3013813T3 (ro)
DO (1) DOP2015000302A (ro)
EA (1) EA028637B1 (ro)
EC (1) ECSP16003103A (ro)
ES (2) ES2729630T3 (ro)
FI (1) FI3421462T3 (ro)
GE (1) GEP20186811B (ro)
GT (1) GT201500350A (ro)
HR (2) HRP20191163T1 (ro)
HU (2) HUE043705T2 (ro)
IL (1) IL242480B (ro)
MA (1) MA38661A1 (ro)
MD (1) MD20150122A2 (ro)
MX (2) MX394241B (ro)
NI (1) NI201500179A (ro)
NZ (1) NZ713762A (ro)
PE (1) PE20160664A1 (ro)
PH (1) PH12015502502A1 (ro)
PL (2) PL3013813T3 (ro)
PT (2) PT3421462T (ro)
RS (2) RS59018B1 (ro)
SG (1) SG11201509186TA (ro)
TN (1) TN2015000547A1 (ro)
TR (1) TR201907981T4 (ro)
TW (1) TWI508957B (ro)
UA (1) UA112945C2 (ro)
UY (1) UY35628A (ro)
WO (1) WO2014207601A1 (ro)
ZA (1) ZA201508252B (ro)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201502763VA (en) 2012-11-08 2015-05-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
JP6026024B2 (ja) 2013-06-27 2016-11-16 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015162516A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CR20160493A (es) 2014-04-25 2016-12-16 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CA2946990A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CN106146404B (zh) * 2015-04-15 2020-03-20 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
SG10201908839QA (en) 2015-10-14 2019-10-30 Bristol Myers Squibb Co 2,4-dihydroxy-nicotinamides as apj agonists
CA3003998A1 (en) 2015-12-18 2017-06-22 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
US11045562B2 (en) 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
ES2837018T3 (es) 2016-01-15 2021-06-29 Pfizer Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina
JP6716711B2 (ja) 2016-03-24 2020-07-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊアゴニストとしての６−ヒドロキシ−４−オキソ−１，４−ジヒドロピリミジン−５−カルボキシアミド
WO2017170759A1 (ja) 2016-03-30 2017-10-05 石原産業株式会社 ピリダジノン系化合物又はその塩、及びそれらを含有する除草剤
EP3590920B1 (en) * 2017-03-02 2025-05-21 Shanghai Institute of Materia Medica, Chinese Academy of Sciences 2-(substituted benzene matrix) aromatic formate fto inhibitor, preparation method therefor, and applications thereof
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
AU2021261383A1 (en) * 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
TW202222163A (zh) * 2020-08-14 2022-06-16 瑞士商先正達農作物保護公司 化學方法
IL313212A (en) 2021-12-03 2024-07-01 Teva Czech Ind S R O Solid state forms of tavapadon and processes for preparation thereof
CN118401513A (zh) * 2022-01-29 2024-07-26 苏州科睿思制药有限公司 他伐帕敦的晶型及其制备方法和用途
WO2025037213A1 (en) * 2023-08-11 2025-02-20 Mankind Pharma Ltd. Pharmaceutical formulations of gpr119 agonists and uses thereof
WO2025144911A1 (en) 2023-12-27 2025-07-03 Pfizer Inc. Solid forms of 6-[4-[[3-(difluoromethoxy)-2-pyridinyl]oxy]-2-methylphenyl]-1,5-dimethyl-2,4(1h, 3h)-pyrimidinedione, a

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5025142B1 (ro) 1969-07-30 1975-08-21
JPS5039272B1 (ro) 1970-07-14 1975-12-16
JPS5025142A (ro) 1973-07-06 1975-03-17
JPS5039272A (ro) 1973-08-10 1975-04-11
JPS5516432B2 (ro) 1974-05-28 1980-05-01
JPS51113899A (en) 1975-03-27 1976-10-07 Yoshitomi Pharmaceut Ind Ltd Method for preparing novel tetrazole derivatives
JPS522031A (en) 1975-06-24 1977-01-08 Japan Niyuupureito Hokushiyou Sunshade device
DE2861615D1 (en) 1978-01-02 1982-03-11 Ciba Geigy Ag Phenoxy-alkyl oxazolines, their preparation, compositions containing them and their application as herbicides
EP0101662A3 (de) 1982-06-25 1985-12-04 Ciba-Geigy Ag Benzoylparabansäuren
US4550108A (en) 1983-08-17 1985-10-29 Ciba Geigy Corporation 1,3,5-Oxadiazine-2,4-diones and pesticidal use
US4723015A (en) 1983-10-17 1988-02-02 Ciba-Geigy Corporation Certain insecticidal N-2-pyridyloxyphenylbenzimidates
IL73611A0 (en) 1983-12-06 1985-02-28 Nippon Soda Co 1,2,4-oxa-and thiadiazolin-3-one derivatives,their preparation and their use as insecticides and fungicides
JPS61275271A (ja) 1985-05-30 1986-12-05 Nippon Soda Co Ltd １，２，４−オキサ（チア）ジアゾリン誘導体、その製造方法，殺虫剤及び農園芸用殺菌剤
DE3545786A1 (de) 1985-12-21 1987-06-25 Schering Ag Pyrazolinderivate, ihre herstellung und ihre verwendung als mittel mit insektizider wirkung
DE3545569A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3631511A1 (de) 1986-09-12 1988-03-24 Schering Ag 5-halogen-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als akarizide und insektizide mittel
EP0296518A1 (de) 1987-06-22 1988-12-28 Ciba-Geigy Ag Neue Phenylether-derivate als Mikrobizide, Verfahren zu deren Herstellung und deren Verwendung
DE3826855A1 (de) * 1988-08-06 1990-02-15 Cassella Ag 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung
JPH0259573A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ２（１ｈ）−ピリミジノン誘導体又はその塩類
JPH0259574A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ピラジノン誘導体又はその塩類
US5066667A (en) 1989-06-26 1991-11-19 Ciba-Geigy Corporation Thioxotetrazolines and insecticidal use thereof
EP0438209B1 (en) 1990-01-18 1994-09-21 Nissan Chemical Industries, Limited Uracil derivatives and pesticides containing the same as active ingredient
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH03261783A (ja) 1990-03-12 1991-11-21 Suntory Ltd １，２，４―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤
DE4030042A1 (de) 1990-05-17 1991-11-21 Bayer Ag Verwendung von substituierten 1,2,4-triazindionen
JP3018422B2 (ja) 1990-07-27 2000-03-13 日東紡績株式会社 床 材
US5630962A (en) 1990-12-19 1997-05-20 Hoechst Aktiengesellschaft 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures
JPH0539272A (ja) 1991-01-09 1993-02-19 Nissan Chem Ind Ltd ピリミジンジオン誘導体および除草剤
JPH0525142A (ja) 1991-07-12 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH05202031A (ja) 1992-01-28 1993-08-10 Nissan Chem Ind Ltd Ｎ−アミノピリミジンジオン誘導体および除草剤
WO1993018016A1 (en) 1992-03-11 1993-09-16 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
US5482951A (en) 1992-05-29 1996-01-09 Kumiai Chemical Industry Co., Ltd. Triazole derivatives as well as insecticide and acaricide
JPH07501084A (ja) 1992-08-31 1995-02-02 チバ−ガイギー　アクチェンゲゼルシャフト ４，５−ジシアノイミダゾール誘導体及びそれらを含む農薬（ｐｅｓｔｉｃｉｄａｌ）組成物
KR0151364B1 (ko) 1992-12-25 1998-10-15 시모무라 도오루 헤테로 고리 유도체 및 유해 생물 방제제
JP3682075B2 (ja) 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
EP0712847A4 (en) 1993-08-11 1997-05-28 Nippon Soda Co IMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS A PEST CONTROL
JPH0873446A (ja) 1994-04-22 1996-03-19 Nippon Soda Co Ltd ヘテロ環化合物および殺虫・殺ダニ剤
JPH0827120A (ja) 1994-07-08 1996-01-30 Nissan Chem Ind Ltd テトラヒドロピリミジノン誘導体
JPH08217777A (ja) 1995-02-10 1996-08-27 Nippon Nohyaku Co Ltd ２−ピラゾリン−５−オン誘導体及びその中間体並びに除草剤
DE19518681A1 (de) 1995-05-22 1996-11-28 Bayer Ag Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH09291282A (ja) 1996-04-26 1997-11-11 Sumitomo Chem Co Ltd 安定化した液晶材料およびこれを用いた液晶素子
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP1030843A4 (en) * 1997-10-27 2002-11-06 Isk Americas Inc SUBSTITUTED BENZENE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND HERBICIDES AND LEAVING COMPOSITIONS THAT CONTAIN THEM
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
AU1130700A (en) 1998-10-23 2000-05-15 Dow Agrosciences Llc Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles
GB9903671D0 (en) 1999-02-17 1999-04-14 Cenes Ltd Dopamine D-1 receptor agonist compounds
KR20020063934A (ko) 2000-01-18 2002-08-07 화이자 프로덕츠 인코포레이티드 코르티코트로핀 방출 인자 길항제
EP1273287A1 (en) 2000-04-04 2003-01-08 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
AU2001268711A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
US6476055B1 (en) 2001-03-28 2002-11-05 Nippon Soda Co. Ltd. 5,5-disubstituted thiazolidine derivative pesticides
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
CN1522251A (zh) 2001-05-09 2004-08-18 ס������ũҩ��ʽ���� 唑化合物及其制备方法和应用
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
AU2003261713A1 (en) 2002-08-26 2004-03-11 Nissan Chemical Industries, Ltd. Substituted benzanilide compound and pest control agent
EP1575919A1 (en) 2002-11-11 2005-09-21 Bayer HealthCare AG Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
US6969744B2 (en) 2003-06-19 2005-11-29 University Of Southern Mississippi Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation
RS20060143A (sr) 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
WO2005051932A1 (ja) 2003-11-28 2005-06-09 Nippon Soda Co., Ltd. アリール複素環誘導体および農園芸用殺菌剤および殺虫剤
JP2005272452A (ja) 2004-02-23 2005-10-06 Nissan Chem Ind Ltd 置換ベンズアニリド化合物及び有害生物防除剤
CA2563356A1 (en) 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
MXPA06012613A (es) 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
TW200612827A (en) 2004-08-25 2006-05-01 Sumitomo Chemical Co Insecticide composition
WO2007016431A2 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel benzo [d] [1,3]-dioxol derivatives
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
GB0524786D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
JP5025142B2 (ja) 2006-02-27 2012-09-12 株式会社東芝 モータ制御装置
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
AU2007246172A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors 3
WO2008035309A2 (en) 2006-09-21 2008-03-27 Piramal Life Sciences Limited Method for identifying compounds that act as insulin-sensitizers
US8269010B2 (en) 2006-09-21 2012-09-18 Piramal Healthcare Limited 3-amino-pyridine derivatives for the treatment of metabolic disorders
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
EP1916240A1 (en) * 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
DE102007003036A1 (de) 2006-12-20 2008-06-26 Bayer Cropscience Ag Pyrimidinylpyrazole
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
WO2008101682A2 (en) 2007-02-22 2008-08-28 Syngenta Participations Ag Iminipyridine derivatives and their uses as microbiocides
AR065622A1 (es) 2007-03-07 2009-06-17 Ortho Mcneil Janssen Pharm Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101294257B (zh) 2007-04-23 2014-06-18 株式会社神户制钢所 焊接热影响部的韧性优异的钢材及其制造方法
JP2009062290A (ja) 2007-09-04 2009-03-26 Takeda Chem Ind Ltd シクロプロパン化合物
BRPI0817101A2 (pt) * 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
NZ582095A (en) * 2007-10-31 2012-08-31 Abbott Gmbh & Co Kg Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2721452A1 (en) 2008-04-16 2009-10-22 Biolipox Ab Bis-aryl compounds for use as medicaments
US20110112193A1 (en) 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
MX2011000175A (es) 2008-06-25 2011-06-27 Envivo Pharmaceuticals Inc Compuestos heterociclicos 1,2-di-substituidos.
CA2736970A1 (en) * 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivatives for use as medicaments
WO2010064688A1 (ja) 2008-12-03 2010-06-10 日本農薬株式会社 ピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
EA020460B1 (ru) 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
EP2246335A1 (de) 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyrimidinamide als Schädlingsbekämpfungsmittel
PT2542084T (pt) * 2010-03-04 2018-03-23 Merck Sharp & Dohme Inibidores de catecol o-metil transferase e sua utilização no tratamento de distúrbios psicóticos
MX2012012353A (es) 2010-04-23 2013-02-07 Kineta Inc Compuestos anti-virales.
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
PE20131116A1 (es) 2010-08-10 2013-10-24 Takeda Pharmaceutical Compuestos heterociclicos potenciadores de ampa
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
TW201331186A (zh) * 2011-09-02 2013-08-01 Purdue Pharma Lp 作為鈉通道阻斷劑之嘧啶類
SG11201502763VA (en) * 2012-11-08 2015-05-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
JP5823657B1 (ja) 2012-11-08 2015-11-25 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物
WO2014119770A1 (ja) * 2013-01-30 2014-08-07 住友化学株式会社 ピリダジノン化合物及びそれを含有する除草剤
JP6026024B2 (ja) * 2013-06-27 2016-11-16 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用

Also Published As

Publication number Publication date
US20190002439A1 (en) 2019-01-03
HUE062265T2 (hu) 2023-10-28
CN105324376A (zh) 2016-02-10
ES2948192T3 (es) 2023-09-01
SG11201509186TA (en) 2016-01-28
UA112945C2 (uk) 2016-11-10
US20170057947A1 (en) 2017-03-02
ES2729630T3 (es) 2019-11-05
NI201500179A (es) 2016-02-11
DK3421462T3 (da) 2023-06-12
US9139561B2 (en) 2015-09-22
MX394241B (es) 2025-03-21
TWI508957B (zh) 2015-11-21
PL3013813T3 (pl) 2019-10-31
GT201500350A (es) 2017-09-28
BR112015030101A2 (pt) 2017-07-25
CA2916653C (en) 2017-07-18
TW201512185A (zh) 2015-04-01
US9107923B2 (en) 2015-08-18
FI3421462T3 (fi) 2023-06-26
US20240317713A1 (en) 2024-09-26
ECSP16003103A (es) 2017-08-31
US20180037571A1 (en) 2018-02-08
EP3421462B1 (en) 2023-04-05
IL242480A0 (en) 2016-02-01
KR101781723B1 (ko) 2017-10-23
AU2014300673A1 (en) 2015-11-12
IL242480B (en) 2019-09-26
EA028637B1 (ru) 2017-12-29
US11014909B2 (en) 2021-05-25
EP3013813A1 (en) 2016-05-04
CL2015003735A1 (es) 2016-06-24
EP3013813B1 (en) 2019-04-03
US10093655B2 (en) 2018-10-09
TR201907981T4 (tr) 2019-06-21
DOP2015000302A (es) 2016-02-29
DK3013813T3 (da) 2019-06-03
US11964961B2 (en) 2024-04-23
CA2916653A1 (en) 2014-12-31
NZ713762A (en) 2018-03-23
MX2015017169A (es) 2016-04-06
US20200283407A1 (en) 2020-09-10
PT3421462T (pt) 2023-06-29
KR20160014665A (ko) 2016-02-11
CU20150180A7 (es) 2016-05-30
ZA201508252B (en) 2019-04-24
PL3421462T3 (pl) 2023-09-11
MA38661A1 (fr) 2017-03-31
JP2016531083A (ja) 2016-10-06
PT3013813T (pt) 2019-06-14
EP3421462A1 (en) 2019-01-02
US20150175573A1 (en) 2015-06-25
US9527831B2 (en) 2016-12-27
AP2015008844A0 (en) 2015-11-30
CN105324376B (zh) 2017-06-23
HK1215435A1 (zh) 2016-08-26
MX382599B (es) 2025-03-13
HRP20230546T1 (hr) 2023-08-04
WO2014207601A1 (en) 2014-12-31
US20210300899A1 (en) 2021-09-30
AU2014300673B2 (en) 2017-12-14
PH12015502502A1 (en) 2016-02-22
BR122023004130B1 (pt) 2023-12-12
US10696658B2 (en) 2020-06-30
US20150005313A1 (en) 2015-01-01
JP6026024B2 (ja) 2016-11-16
US20150196561A1 (en) 2015-07-16
RS64342B1 (sr) 2023-08-31
CU24334B1 (es) 2018-04-03
US9822097B2 (en) 2017-11-21
GEP20186811B (en) 2018-01-25
MX2020013099A (es) 2022-07-26
AR096748A1 (es) 2016-02-03
HRP20191163T1 (hr) 2019-10-04
US10421744B2 (en) 2019-09-24
RS59018B1 (sr) 2019-08-30
PE20160664A1 (es) 2016-07-09
CR20150634A (es) 2016-01-04
US20190367485A1 (en) 2019-12-05
HUE043705T2 (hu) 2019-09-30
UY35628A (es) 2015-01-30
EA201592146A1 (ru) 2016-05-31
TN2015000547A1 (fr) 2017-04-06

Similar Documents

Publication Publication Date Title
MD20150122A2 (ro) Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
NZ713809A (en) 3,4-dihydroisoquinolin-2(1h)-yl compounds
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
PH12015502524B1 (en) New somatostatin receptor subtype 4 (sstr4) agonists
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
IN2014DN09826A (ro)
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
TN2015000524A1 (en) Pharmaceutical compositions
CA2863110A1 (en) 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
HK1199014A1 (en) Mglu 2/3 agonists
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
IN2013MU03838A (ro)

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)